Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NORVASC®Highlights (amlodipine besylate)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use NORVASC safely and effectively. See full prescribing information for NORVASC.
 
NORVASC® (amlodipine besylate) Tablets for oral administration
Initial U.S. Approval: 1992

INDICATIONS AND USAGE

NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of:

  • Hypertension (1.1)
    • NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • Coronary Artery Disease (1.2)
    • Chronic Stable Angina
    • Vasospastic Angina (Prinzmetal's or Variant Angina)
    • Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%

DOSAGE AND ADMINISTRATION

  • Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. (2.1)
    • Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily. (2.1)
  • Pediatric starting dose: 2.5 mg to 5 mg once daily. (2.2)

Important Limitation: Doses in excess of 5 mg daily have not been studied in pediatric patients. (2.2)

DOSAGE FORMS AND STRENGTHS

  • Tablets: 2.5 mg, 5 mg, and 10 mg (3)

CONTRAINDICATIONS

  • Known sensitivity to amlodipine (4)

WARNINGS AND PRECAUTIONS

  • Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely. (5.1)
  • Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORVASC, particularly in patients with severe obstructive coronary artery disease. (5.2)
  • Titrate slowly in patients with severe hepatic impairment. (5.3)

ADVERSE REACTIONS

Most common adverse reaction to amlodipine is edema which occurred in a dose related manner. Other adverse experiences not dose related but reported with an incidence >1.0% are fatigue, nausea, abdominal pain, and somnolence. (6)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or www.pfizer.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Do not exceed doses greater than 20 mg daily of simvastatin. (7.2)

USE IN SPECIFIC POPULATIONS

  • Pediatric: Effect on patients less than 6 years old is not known. (8.4)
  • Geriatric: Start dosing at the low end of the dose range. (8.5)

See 17 for FDA-approved patient labeling.

Revised: 1/2019

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event